Immunohistochemical expression in male breast cancer: two case reports
- PMID: 16793559
- PMCID: PMC11917649
- DOI: 10.1016/S1607-551X(09)70242-6
Immunohistochemical expression in male breast cancer: two case reports
Abstract
Male breast cancer is rare, and the incidence is less than 1% of all breast malignancies in both men and women. It is possible that, because male patients are unaware of male breast cancer, there is a delay of diagnosis and, consequently, more advanced stages are commonly encountered in these patients. Some studies have engaged in molecular studies of male breast cancers because of the possibly different characteristics, prognosis, and treatment between male and female malignancies. However, a dearth of studies still exists, most likely because of the rarity of the disease and lack of a large patient base for study. Among the molecular markers of breast cancer, p53, Ki-67, HER-2/neu, and Bcl-2 are the most frequently studied. Here we present two rare cases and a review of the literature concerning the relationship between immunohistochemical markers and their impact in order to provide surgeons with more information about the disease and further techniques for treatment of these patients.
Similar articles
-
Prognostic value of bcl-2, p53 and Ki-67 in invasive squamous carcinoma of the uterine cervix.Eur J Gynaecol Oncol. 2000;21(3):267-72. Eur J Gynaecol Oncol. 2000. PMID: 10949392
-
Proliferative activity (Ki-67), WT p53, Bcl-2 expression and their relationship to the tumor grade, in invasive ductal breast carcinomas.In Vivo. 2002 Mar-Apr;16(2):141-4. In Vivo. 2002. PMID: 12073773
-
The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.Cancer. 1997 Sep 15;80(6):1034-45. Cancer. 1997. PMID: 9305703
-
[p53, bcl-2 and Ki-67 in the diagnosis of insular thyroid gland cancer. Case report with a review of literature].Lijec Vjesn. 2006 Sep-Oct;128(9-10):264-7. Lijec Vjesn. 2006. PMID: 17128663 Review. Croatian.
-
Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature.Crit Rev Oncol Hematol. 2017 May;113:283-291. doi: 10.1016/j.critrevonc.2017.03.013. Epub 2017 Mar 29. Crit Rev Oncol Hematol. 2017. PMID: 28427518 Review.
Cited by
-
Male breast cancer: is the scenario changing.World J Surg Oncol. 2008 Jun 16;6:58. doi: 10.1186/1477-7819-6-58. World J Surg Oncol. 2008. PMID: 18558006 Free PMC article. Review.
References
-
- Kidmas AT, Ugwu BT, Manasseh AN, et al. Male breast malignancy in Jos University Teaching Hospital. West Afr J Med. 2005; 24: 36–40. - PubMed
-
- Schuchardt U, Seegenschmiedt MH, Kirschner MJ, et al. Adjuvant radiotherapy for breast carcinoma in men: a 20‐year clinical experience. Am J Clin Oncol. 1996; 19: 330–336. - PubMed
-
- Weber‐Chappuis K, Bieri‐Burger S, Hurlimann J. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer. 1996; 32A: 1686–1692. - PubMed
-
- Daltrey IR, Eeles RA, Kissin MW. Bilateral prophylactic mastectomy: not just a woman's problem. Breast. 1998; 7: 236–237.
-
- Ravandi‐Kashani F, Hayes TG. Male breast cancer: a review of the literature. Eur J Cancer. 1998; 34: 1341–1347. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous